Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older, of any gender
• People who have been confirmed by tissue testing to have unresectable (cannot be surgically removed) stage III or IV stomach cancer or cancer of the junction between the stomach and oesophagus, where testing shows a specific genetic feature called dMMR (meaning at least one of four proteins — MLH1, PMS2, MSH2, or MSH6 — is completely absent); neuroendocrine tumours are not included
• People whose cancer has spread but where doctors consider there may be a possibility of converting to surgery after treatment — for example, those with spread to a single organ (such as the liver, ovaries, or lungs), nearby lymph nodes, limited spread to the lining of the abdomen, or cancer growing into surrounding organs
• People who have not yet had surgery, radiation therapy, or immunotherapy for their stomach cancer or any spread of that cancer
• People with a good general level of daily functioning, rated 0 or 1 on the ECOG performance scale (confirm with trial site)
• People with a life expectancy of at least 3 months
• People whose major organs — including blood, heart, lungs, liver, kidneys, and bone marrow — are all functioning within normal ranges
• People with normal blood clotting and no active bleeding or clotting conditions
• People who finished taking certain anti-tumour traditional Chinese medicines or immune-boosting medicines (such as thymosin or interleukin) at least 2 weeks before the study starts
• Women of childbearing age who agree to use an approved contraceptive method during the study and for 180 days after treatment ends, have a negative pregnancy blood test within 72 hours before joining, and are not breastfeeding; women who have had non-surgical sterilisation must also meet these requirements (confirm with trial site)
• Male participants whose partners could become pregnant must agree to use effective contraception during the study and for 180 days after treatment ends
• People who voluntarily agree to take part, have been fully informed about the study, and have signed the consent form

Who may not be able to join:

• People diagnosed with another cancer in the past 5 years, unless it was certain skin cancers, cervical cancer in situ, breast cancer, or thyroid cancer that was successfully treated and has achieved long-term survival
• People with an active autoimmune disease or a history of one — such as autoimmune lung, eye, gut, liver, brain, blood vessel, heart, or kidney conditions, or thyroid problems that are not stable with treatment; people with childhood asthma that has fully resolved or vitiligo may still be considered, but those needing inhalers to manage breathing may not be
• People with immune system deficiencies, including those with HIV, active hepatitis B (with virus levels above a certain threshold), active hepatitis C (confirmed by blood testing), or both hepatitis B and C together
• People who have taken immune-suppressing medications within 14 days before starting the study, with some exceptions for low-dose or inhaled steroids (confirm with trial site)
• People who have received a live attenuated vaccine within 4 weeks before starting the study, or who plan to receive one during the study period
• People with high blood pressure that cannot be brought within an acceptable range (below 140/90 mmHg) even with blood pressure medications
• People with significant uncontrolled heart conditions, including moderate-to-severe heart failure, unstable chest pain, a heart attack within the past year, or poorly controlled irregular heartbeat
• People who have had or currently have serious lung conditions such as interstitial lung disease, dust-related lung disease, radiation-related lung damage, or drug-related lung damage, where lung function is significantly impaired
• People with active tuberculosis
• People who have had a serious infection requiring intravenous antibiotics, antifungal, or antiviral treatment within 4 weeks before starting the study, or who have an unexplained fever of 38.5°C or higher during the screening period
• People who have had an organ transplant or bone marrow/stem cell transplant from a donor
• People with a known allergy to any of the medicines used in this trial
• People with other severe or uncontrolled medical conditions that could increase the risks of participating (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.